In SURMOUNT 1, tirzepatide induced a mean BW reduction of 15.0%, 19.5% and 20.9% with 5 mg, 10 mg and 15 mg, respectively compared to 3.1% obtained with placebo at 72 weeks 34
Its smooth texture glides on effortlessly, nourishing dry skin and softening rough patches
31, 2000 and held through March 31, 2016
Who its for May be a fit if you Would rather avoid needles Are exploring provider-guided weight management Are navigating weight changes in perimenopause or menopause Want licensed provider oversight and ongoing support Not appropriate if you Have a personal or family history of medullary thyroid carcinoma or MEN 2 Are pregnant, trying to conceive, or breastfeeding Have a history of pancreatitis or certain GI conditions (discuss with your provider) Are advised against GLP-1 care by your provider Eligibility is always determined by a licensed provider after reviewing your intake
After that, the medical team may recommend reducing the dose, spacing out the injections, or stopping the medication while focusing on weight maintenance.